Cadrenal Therapeutics (CVKD) Other Accumulated Expenses (2022 - 2026)

Cadrenal Therapeutics has reported Other Accumulated Expenses for 5 years, with the latest figure at $83527.0 in Q1 2026.

• Quarterly Other Accumulated Expenses rose 236.76% year-over-year to $83527.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $83527.0 (up 236.76% YoY) and the FY2025 annual result came in at $38771.0, down 17.06% from the prior year.
• Other Accumulated Expenses climbed to $83527.0 in Q1 2026 per CVKD's latest filing, from $38771.0 in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $150993.0 in Q1 2024 and troughed at $24803.0 in Q1 2025.
• A 5-year average of $59663.2 and a median of $46240.0 in 2024 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2025 and 2026: Other Accumulated Expenses slumped 83.57% in 2025, then surged 236.76% in 2026.
• Over 5 years, Other Accumulated Expenses stood at $93082.0 in 2022, then plunged by 59.1% to $38075.0 in 2023, then climbed by 22.77% to $46744.0 in 2024, then retreated by 17.06% to $38771.0 in 2025, then surged by 115.44% to $83527.0 in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $83527.0, $38771.0, and $35614.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.